Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Human basal-like breast cancer cell line HCC1143 treated with BET inhibitor JQ1 in combination with MEK inhibitor Trametinib or PI3K/mTOR inhibitor BEZ235

ABSTRACT: The goal of this experiment was to understand the changes in gene expression in the human basal-like breast cancer cell line HCC1143 following treatment with the MEK inhibitor Trametinib (T), PI3K/mTOR inhibitor BEZ235 (B), the BET inhibition JQ1 (JQ), Trametinib + JQ1 (TJ), or BEZ235 + JQ1(BJ), compared to a DMSO control (D). Samples were treated for 72hr and run in triplicate.

ORGANISM(S): Homo sapiens

PROVIDER: GSE82032 | GEO | 2017/05/30

SECONDARY ACCESSION(S): PRJNA323723

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptomic analysis of T84 colon carcinoma cell line treated with trametinib, JQ1 or their combination

Project description:T84 cells were treated with DMSO, 30nM trametinib (MEKi), 1µM JQ1 (BRD4i) or the combination of trametinib and JQ1 (combo) for 24h.

2018-10-23 | GSE118548 | GEO

Project description:LP-WGS of HCC1143 breast cancer cells treated with Trametinib, BEZ235, or DMSO

| PRJNA454331 | ENA

Gene expression and alternative splicing profiles of BEZ235 treated Ewing Sarcoma cells

Project description:TC71 cells treated either with BEZ235 or DMSO

2018-02-14 | GSE93579 | GEO

Homo sapiens

Project description:Human basal-like breast cancer cell line HCC1143 treated with BET inhibitor JQ1 in combination with MEK inhibitor Trametinib or PI3K/mTOR inhibitor BEZ235

| PRJNA323723 | ENA

Influence of BEZ235 and MYC on gene expression in SW620 cells

Project description:SW620 were transfected with siMYC or siCTR at time point 0h. 24h later cells were splitter 1:2, additional 24 h later (48h after transfection) cells were treated with BEZ235 (200nM) or DMSO. Cells were harvested after additional 24h (72h after siRNA transfection; 24h BEZ235 treatment.

2015-08-27 | E-MTAB-2882 | biostudies-arrayexpress

High efficacy of combined MEK Inhibitor Trametinib and RTK Inhibitor Anlotinib Therapy in KRAS-Mutant Lung Cancer

Project description:Oncogenic KRAS mutations frequently detected in non-small cell lung cancer (NSCLC)1,2, have been considered undruggable until recent development of inhibitors, e.g., sortorasib, adagrasib or divarasib, specifically targeting KRASG12C 3-6. However, it still remains as a big challenge to target all the KRAS mutants besides KRASG12C 2,7,8. We here found that MEK inhibitor trametinib treatment results in the feedback activation of multiple receptor tyrosine kinases (RTKs) in NSCLC, and combined treatments with trametinib and anlotinib, a pan-RTK inhibitor, effectively inhibited KRAS-mutant lung cancer progression.

2024-11-11 | GSE247512 | GEO

RNA seq NVP-BEZ235 treatment of U87MG cells

Project description:Glioblastoma (GBM) is the most lethal primary brain cancer that lacks effective molecular targeted therapies. PI3K/AKT/mTOR signaling pathway is activated in 90% of all Glioblastoma Multiforme (GBM) tumors. To gain insight into the impact of the PI3K Pathway on GBM metabolism, we treated U87MG GBM cells with 50nM NVP-BEZ235 (PI3K and mTOR a dual inhibitor) for four days and identified differentially expressed genes with RNA-seq analysis.

2021-12-01 | GSE179667 | GEO

Gene expression changes induced by the BET inhibitor GSK525762 and/or the MEK inhibitor trametinib in cancer cell lines.

Project description:Transcriptional changes were analyzed in two colorectal cancer, two pancreatic cancer, and one small cell lung cancer cell line following treatment with the BET inhibitor GSK525762 and/or the MEK inhibitor trametinib using Affymetrix Human Genome U133 Plus 2.0 Arrays.

2018-04-20 | GSE112282 | GEO

RNA seq NVP-BEZ235 treatment of U87MG cells

Project description:RNA seq NVP-BEZ235 treatment of U87MG cells

| PRJNA744516 | ENA

Differentially expressed genes in iKRAS cell treated with Trametinib, 2DG and Combo

Project description:To identify the differentially expressed gene in ikras cells treated with Trametinib, 2DG and Trametinib/2DG combination. Two ikras cells were used for transcriptomics analysis by RNAseq.

2021-06-07 | GSE176242 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data